Market: Overview

Peptide Cancer Vaccine Market was USD 4,720 million in the year 2022. It is expected to reach USD 10,070 million with a Compound Annual Growth Rate (CAGR) of 11.2% by the end of 2032.

Due to an increase in the prevalence of cancer and failure of conventional methods for the treatment of the disease, it has effectively led to an increase in demand for new immunotherapy-based therapies, such as peptide vaccine.

Manufacturers are also involved in mergers and acquisitions and new product launches in the peptide cancer vaccine market to cater to the increasing demand for vaccines. Further, the industry is adopting sustainable solutions for vaccine which can lead to further growth.

Peptide Cancer Vaccine Market: Description

Peptide Cancer Vaccine provides tumour specific T-cells to control or eradicate cancer. The vaccine contains tumour antigens in the form of short or long amino acid sequences.

The usage of Peptide Cancer Vaccine is to control tumour growth in mouse models which is expected to propel the growth of Peptide Cancer Vaccine Market. In the recent past, results of clinical trials performed using peptide cancer vaccine has shown negative outcomes.

The advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, and easy to prepare. Its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to increase the growth of the peptide cancer vaccine market in the near future.

Peptide Cancer Vaccine Market: Key Trends

·   Major Players Emphasize on the Research Activities to Develop Peptide Vaccine to grow the Market Demand

Peptide Cancer Vaccines have various advantages such as, they are easy to prepare, easy to synthesize, cost-effective, helpful in clinical practices, have lower risk of antigen-induced anaphylaxis, and are flexibility in changing antigen. All these advantages are responsible for increasing the growth of Peptide Cancer Vaccine Market in coming years.

In addition, various key players are also investing in research activities to produce Peptide Cancer Vaccines because of its beneficial advantages. We can consider an example of, Boston Biomedical, Inc., which is a global developer of novel cancer therapeutics that announced the evaluation of DSP-7888, an investigational WT1 cancer peptide vaccine to investigate the safety, tolerability, and determination of the recommended phase 2 dose of DSP-7888 in patients.

·  Provision of Healthy Features of Peptide Vaccine than Conventional Therapies that drive the Market

The Peptide Cancer Vaccines have good features in terms of better safety and tolerance than conventional methods such as, immune checkpoint inhibitors and chemotherapy. The growing prevalence of cancer and presence of good characteristics of these vaccines are accelerating the demand for Peptide Cancer Vaccine Market during the given time period.

According to International Agency for Research on Cancer, worldwide around 19.3 million new cancer cases are estimated and almost 10.0 million cancer deaths have occurred in 2020. Among these, major cases observed for breast, lung, colorectal, prostate, and stomach cancers. It has shown an increase in the demand for Peptide Cancer Vaccine Market in coming years.

Impact of Covid-19 on the Market

The COVID-19 pandemic has had a significant impact on the healthcare industry, including the peptide cancer vaccine market. However, with the ongoing vaccination campaigns and the gradual reopening of economies, the peptide cancer vaccine market is expected to recover in the coming years. Here are some potential factors that could contribute to the recovery of the peptide cancer vaccine market from COVID-19:

·  Increasing awareness about cancer and its treatment: The COVID-19 pandemic has put a spotlight on the importance of healthcare, and as a result, people are becoming more aware of the risks associated with cancer. This could lead to an increase in demand for cancer treatments, including peptide cancer vaccines.

·  Government initiatives and funding: Governments across the world are investing heavily in healthcare infrastructure and research to combat the COVID-19 pandemic. This could result in increased funding for cancer research and vaccine development, which would ultimately benefit the peptide cancer vaccine market.

·      Improved healthcare access: The pandemic has highlighted the importance of universal healthcare and access to treatments for all. This could lead to improved healthcare access for cancer patients, which would increase demand for peptide cancer vaccines.

·     Technological advancements: The pandemic has accelerated the adoption of telemedicine and digital healthcare solutions, which could improve the efficiency and accessibility of cancer treatments, including peptide cancer vaccines.

In conclusion, while the COVID-19 pandemic has had a significant impact on the peptide cancer vaccine market, there are several factors that could contribute to its recovery in the coming years.

Peptide Cancer Vaccine Market: Segmentation Analysis

Cancer Vaccine Market Key Players:

TapImmune

Merck

BrightPath Biotherapeutics

Sellas

BioLife Science

Boston Biomedical

VAXON Biotech

Lytix Biopharma

ISA Pharmaceuticals

Generex Biotechnology

Onco Therapy Science

Enzo Life Science

Antigen Express

Immatics Biotechnologies

Immune Design

Immunomedics

Galena Biopharma

Generex Biotechnology Corporation

Ultimovacs

Peptide Cancer Vaccine Market based on Product Type:

• Personalized Peptide Vaccine

• Peptide-Pulsed Dendritic Cancer Vaccine

• Peptide Cocktail Type

• Multivalent Peptide Vaccine

• Others

Personalized Peptide Vaccines are immunotherapeutic approach and is based on the administration of multiple cancer peptides. It is developed from patient’s own tumor cells. While, peptide-pulsed dendritic cancer vaccine is used to treat patients with stage IV melanoma.

Peptide Cancer Vaccine Market based on Pipeline Phase

• Research

• Preclinical

• Phase-I

• Phase I/II

• Phase-II

• Phase-III

The research segment is anticipated to amplify significantly over the forecast duration due to rise in government funding to facilitate research and development activities in the field.

Peptide Cancer Vaccine Market based on Application:

• Breast Cancer

• Lung Cancer

• Gastric Cancer

• Prostate Cancer

• Pancreatic Cancer

• Colorectal Cancer

Breast Cancer is the type of cancer that forms in the cells of the breasts. It can occur in women and rarely in men. The symptoms of breast cancer are that there is a lump in the breast, bloody discharge from the nipple, and changes in the shape or texture of the nipple or breast.

Whereas, Lung Cancer is a cancer that begins in the lungs and mostly occurs in people who smoke. The two types of lung cancer include non-small cell lung cancer and small cell lung cancer. Causes of lung cancer includes smoking, second-hand smoke, exposure to certain toxins and family history.

Peptide Cancer Vaccine Market: Regional Analysis

Emerging economies that includes North America, Europe, Asia Pacific and Latin America are set to collect most of the growth in the Peptide Cancer Vaccine Market in coming years.

North America: North America is one of the largest markets for peptide cancer vaccines, with the United States being the primary contributor. The high prevalence of cancer in the region and the presence of major pharmaceutical companies in the US are the key drivers for market growth in North America.

Europe: Europe is another major market for peptide cancer vaccines, with countries like Germany, France, and the UK being major contributors. The high incidence of cancer and the presence of established healthcare infrastructure in the region are the key factors driving the market's growth in Europe.

Asia Pacific: The Asia Pacific region is expected to witness significant growth in the peptide cancer vaccine market due to the high prevalence of cancer in countries like China and India. Additionally, the increasing healthcare expenditure and growing awareness about cancer treatments are driving market growth in the region.

Latin America: The Latin America peptide cancer vaccine market is expected to witness steady growth due to the increasing incidence of cancer in the region and the presence of established pharmaceutical companies.

Middle East and Africa: The Middle East and Africa region are expected to witness moderate growth in the peptide cancer vaccine market due to the increasing incidence of cancer in the region and the rising healthcare expenditure.

Report Scope:

• Peptide Cancer Vaccine Market Forecast Years: 2023-2032

• Peptide Cancer Vaccine Market 2022: USD 4,720 million

• Peptide Cancer Vaccine Market 2032: USD 10,070 million

• Peptide Cancer Vaccine Market CAGR: 11.2%

• Key Segments: Product Type, Pipeline Phase, and Application

• Key Regions and Countries: North America; Europe; Asia Pacific; Latin America